MediWound (NASDAQ:MDWD) Rating Reiterated by HC Wainwright

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $28.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 66.57% from the company’s previous close.

A number of other brokerages also recently weighed in on MDWD. StockNews.com upgraded shares of MediWound to a “sell” rating in a research report on Monday, August 5th. Maxim Group boosted their price objective on shares of MediWound from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th.

MediWound Price Performance

MediWound stock opened at $16.81 on Friday. The company has a market capitalization of $156.06 million, a PE ratio of -12.18 and a beta of 0.83. MediWound has a one year low of $7.45 and a one year high of $24.00. The business has a 50 day simple moving average of $17.60 and a 200 day simple moving average of $17.24.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). The company had revenue of $5.06 million for the quarter, compared to analyst estimates of $5.07 million. MediWound had a negative return on equity of 52.49% and a negative net margin of 99.17%. Equities analysts anticipate that MediWound will post -2.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several institutional investors and hedge funds have recently modified their holdings of MDWD. Rhumbline Advisers bought a new stake in MediWound in the 2nd quarter valued at $131,000. Bank of New York Mellon Corp bought a new position in MediWound in the 2nd quarter valued at approximately $342,000. Rosalind Advisors Inc. grew its stake in shares of MediWound by 5.7% in the second quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock worth $7,969,000 after purchasing an additional 27,500 shares during the last quarter. Essex Investment Management Co. LLC boosted its holdings in MediWound by 241.6% in the first quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after acquiring an additional 93,705 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in MediWound during the first quarter worth $427,000. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.